Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Premier Health Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
44,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
271
States / cities
Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 22, 2026, 7:18 PM EDT
Recruiting Not applicable Interventional

Freedom-1 Study for Chronic Knee Pain

NCT03877653
View directory record Official record
Conditions
Osteoarthritic Knee Pain
Interventions
Wireless neuromodulation
Device
Lead sponsor
Curonix LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Placentia, California • Denver, Colorado • Fort Lauderdale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

NCT04143659
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
levonorgestrel butanoate (LB) injection
Biological
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
7
States / cities
Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception

NCT02173808
View directory record Official record
Conditions
Contraceptive Usage
Interventions
levonorgestrel butanoate
Biological
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

NCT03455075
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

NCT00274261
View directory record Official record
Conditions
Pregnancy
Interventions
C31G, nonoxynol-9 (N-9)
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

NCT03124160
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
Mona Lisa® NT Cu380 Mini, ParaGard® TCu380A
Drug
Lead sponsor
FHI 360
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 22, 2026, 7:18 PM EDT
Not listed Phase 3 Interventional

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

NCT03023540
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Type IA
Interventions
PXT3003
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
17 Years to 67 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

NCT02994602
View directory record Official record
Conditions
Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

NCT01166412
View directory record Official record
Conditions
Contraception
Interventions
levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

NCT03452111
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
9
States / cities
Sacramento, California • Torrance, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

NCT01586000
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
8
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT02754687
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11βmethyl nortestosterone dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT03298373
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11β-methyl-nortestosterone-dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effectiveness of BufferGel as a Vaginal Contraceptive

NCT00065858
View directory record Official record
Conditions
Pregnancy
Interventions
BufferGel
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
975 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

NCT03432416
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
NES-E2 CVR
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679
View directory record Official record
Conditions
Focus: Estrogen-free Oral Contraception
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 22, 2026, 7:18 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

NCT03296098
View directory record Official record
Conditions
Contraception, Healthy Female
Interventions
Ulipristal acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 22, 2026, 7:18 PM EDT
Not yet recruiting Not applicable Interventional

AI-Augmented Motivational Interviewing Training for Primary Care

NCT06597123
View directory record Official record
Conditions
Multiple Chronic Conditions, Patient Engagement, Burnout, Professional, Motivational Interviewing, Implicit Bias
Interventions
Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training, Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training
Behavioral
Lead sponsor
Wright State University
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

NCT01223313
View directory record Official record
Conditions
Contraception
Interventions
Woman's Condom
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring

NCT00455156
View directory record Official record
Conditions
Contraception
Interventions
150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1Phase 2 Interventional

Barriers to Treatment in Obese Adolescents

NCT00167830
View directory record Official record
Conditions
Obesity
Interventions
Motivational Interviewing, Strength and Cardiovascular Conditioning, Food selection and portion control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 18 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone

NCT02626208
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
Nestorone®/Estradiol Contraceptive Vaginal Ring
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
Sacramento, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

NCT00891228
View directory record Official record
Conditions
Contraception
Interventions
Testosterone, Nestorone®
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 22, 2026, 7:18 PM EDT